Development of a novel senolytic by precise disruption of FOXO4-p53 complex

EBioMedicine. 2021 Dec:74:103693. doi: 10.1016/j.ebiom.2021.103693. Epub 2021 Nov 9.

Authors

Utkarsh Tripathi¹, Selim Chaib¹, Erin O Wissler Gerdes¹, Kelly A Hogan², Yi Zhu³

Affiliations

¹ Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
² Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA; Laboratory of Metabolism and Molecular Nutrition, Mayo Clinic, Rochester, MN, USA.
³ Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA. Electronic address: [email protected].

No abstract available

Publication types

Letter

MeSH terms

Apoptosis / drug effects
Cell Cycle Proteins / metabolism*
Drug Development*
Forkhead Transcription Factors / metabolism*
Humans
Multiprotein Complexes / antagonists & inhibitors*
Multiprotein Complexes / metabolism*
Protein Binding / drug effects
Senotherapeutics / pharmacology*
Signal Transduction / drug effects
Tumor Suppressor Protein p53 / metabolism*

Substances

Cell Cycle Proteins
FOXO4 protein, human
Forkhead Transcription Factors
Multiprotein Complexes
Senotherapeutics
Tumor Suppressor Protein p53